KHENERFIN study locations

The first phase of the study will begin at 10 locations across 8 countries, including sites in the European Union and the United States.

Europe and UK

Radboud University Medical Centre, Nijmegen, Netherlands. PI: Mirian Janssen, MD, PhD.
Righospitalet, University of Copenhagen, Copenhagen, Denmark. PI: John Vissing, MD, PhD.
LMU Klinikum, München, Germany. PI: Thomas Klopstock, MD, PhD.
University College London Hospital Trust, Londen, UK. PI: Robbert Pitceathly, MD, PhD.
IRCCS Istituto Carlo Besta, Milano, Italy. PI: Costanza Lamperti MD, PhD.
Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France. PI: Aurélien Trimouille, MD, PhD.
ICM (Paris Brain Institute) in collaboration with APHP (Assistance Publique Hôpitaux de Paris), Paris, France. PI: Fanny Mochel MD, PhD.

Massachusetts General Hospital, Boston, USA. PI: Amel Karaa, MD, PhD.
University of Texas Health Science Center, Houston Texas, USA. PI: Mary Kay Koenig, MD, PhD.
Cleveland Clinic, Cleveland USA. PI: Sumit Parikh, MD, PhD.